Pioneering in antibiotics: Roche’s fight against antimicrobial resistance (AMR)
:quality(90)/)
Antimicrobial resistance (AMR) is a major global health security challenge. It occurs when bacteria evolve to resist the medicines designed to kill them, resulting in an estimated 1.2 million deaths from bacterial AMR in 2019. The lack of effective antibiotics is threatening modern medicine, making essential preventive and life-saving interventions increasingly difficult and allowing hospital-acquired infections to spread.
Beyond the individual burden, the impact of AMR on national economies is significant and will further increase as prolonged illness affects the productivity of patients and their caregivers. For example, it has been estimated that AMR has cost health systems in Europe more than 9 billion euros per year. In the USA, it is estimated that AMR adds 20 billion dollars to direct healthcare costs and costs about 35 billion dollars in productivity losses annually.1
At Roche, we are highly committed and uniquely placed to help counter the threat of antimicrobial resistance (AMR). We are developing both diagnostic technologies and antibiotics with novel mechanisms of action against priority bacterial pathogens identified by the WHO. We also work with partners, including the AMR Action Fund and the AMR Industry Alliance.
We are working with partners across sectors to ensure a global response backed by real action in countries around the world. We are at the forefront of innovation, and we hope this excellence serves as an inspiration for the global effort against bacterial infections. Our commitment is driven by the relentless effort to push the boundaries of R&D science. We know that every discovery in antibiotic therapy is more than just a scientific breakthrough - it is also a source of hope.
AMR
is one of the 10 global public health threats currently facing humanity declared by the WHO
1.2 million
deaths attributable to bacterial AMR in 20192
10 million people
AMR could claim as many as 10 million people per year by 20503
12 antibiotics
2023, the WHO classified as innovative only 12 antibiotics in clinical development that address the WHO list of priority pathogens4
80%
of candidates originating from small companies5
AMR Action Fund
Deliver 2-4 novel antibiotics by 2030 is the objective of the AMR Action Fund
Antimicrobial Resistance (AMR) – Frequently Asked Questions
The history of antibiotics development

Explore and learn
Stories
Read more about Roche's work in the field of antibiotics
Podcast
Antibiotic Resistance: A Call to ArmsStories
Read more about Roche's work in the field of antibiotics
References:
Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019. https://pmc.ncbi.nlm.nih.gov/articles/6929930
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022. https://doi.org/10.1016/S0140-6736(21)02724-0
WHO. New report calls for urgent action to avert antimicrobial resistance crisis, 29 April 2019. https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis
WHO. 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis. 2024. https://www.who.int/publications/i/item/9789240094000
BIO. The State of Innovation in Antibacterial Therapeutics, February 2022. https://www.bio.org/press-release/new-bio-report-examines-state-antibacterial-innovation
WHO. Antimicrobial resistance (fact sheet). https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
United Nations General Assembly. General Assembly adopts Political Declaration on Antimicrobial Resistance(GA/12642), October 2024. https://press.un.org/en/2024/ga12642.doc.htm
WHO. WHO updates list of drug-resistant bacteria most threatening to human health, 17 May 2024 (Bacterial Priority Pathogens List 2024). https://www.who.int/News/Item/17-05-2024-Who-Updates-List-of-Drug-Resistant-Bacteria-Most-Threatening-to-Human-Health
Zampaloni C, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024. https://doi.org/10.1038/s41586-023-06873-0
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)
:quality(90)/)